The basic structure of single-chain antibody (scFv) is to connect the light chain variable region (VL) and heavy chain variable region (VH) of the antibody to form a functional single-chain molecule. VL contains three complementary determining regions (CDRs) that directly interact with specific parts of the antigen. VH contains three CDR structures, which together with VL form the antigen binding site of the antibody. The binding of VH and VL is critical for the specificity of antibody recognition. The two variable regions (VL and VH) are connected by flexible peptide chains, so that they are appropriately close to each other in space to form a complete antigen binding site. Through genetic engineering techniques, the scFv coding sequence can be cloned into a suitable vector, expressed and produced in various hosts.

Because scFv antibodies are small, they can penetrate tissues more easily, which is particularly important for tumor targeted therapy. 

The sequence of scFv can be easily modified by genetic engineering to improve its specificity, affinity, or other functions. 

scFv antibody has good thermal stability and chemical stability, and can maintain activity under different conditions.

scFv antibody can be expressed in bacteria, yeast or mammalian cells, reducing production costs.

scFv antibodies usually have low immunogenicity due to their humanized design, reducing side effects in clinical use.

The sequence of scFv antibody variable region was determined. This step involves the selection of the optimal antibody sequence to ensure high specificity and binding affinity to the target antigen. The key aspect of the cloning sequence design phase is to make a linker peptide with flexibility and stability, connecting the light chain variable region (VL) and the heavy chain variable region (VH) domains, so that the scFv molecule can be correctly folded and expressed. The next step is to synthesize DNA fragments corresponding to the VL and VH amino acid regions. Typically, this involves the use of PCR (polymerase chain reaction) to amplify these gene fragments. The amplified genes were then ligated by overlap extension PCR to form a single scFv coding sequence. The complete gene was inserted into an expression vector such as pET or pGEX, which is helpful for the subsequent expression of scFv protein in host cells.

Protein is generally carried out by affinity tags in scFv cloning vector, such as His tag or FLAG tag, which are combined with nickel or specific resin and purified by affinity chromatography. Other steps, such as gel filtration chromatography, help to separate correctly folded monomer scFv from aggregates and impurities according to the size exclusion principle.

The success of expression and purification was initially evaluated using SDS-PAGE, which provided information on the molecular weight and purity of scFv. The specificity and expression efficiency were further confirmed by Western Blot analysis. In order to evaluate the binding activity and affinity, techniques such as ELISA, surface plasmon resonance (SPR) or biolayer interference (BLI) were used to provide detailed insights into the interaction between scFv and its target antigen.

Figure 1: Antibody model showing subunit composition and do-main distribution along the polypeptide chains. Single-chain frag-ment variable (scFv) antibody generated by recombinant antibodytechnology appears in the shaded area. (Reference source: scFv antibody: principles and clinical application.）

Figure 2: Structure of a filamentous phage displaying scFv frag-ments on its surface. (Reference source: scFv antibody: principles and clinical application.）

scFv antibodies can be combined with drugs or radioisotopes to target specific cancer cells, thereby improving the accuracy and effectiveness of treatment. 

As a detection reagent, scFv can be used in ELISA and other immunoassay techniques to help identify specific proteins or pathogens. 

In basic research, scFv antibodies are often used for protein detection and purification, and also for studying protein-protein interactions. 

scFv antibodies can be developed to block viral entry into host cells, potentially for antiviral therapy.

By blocking specific cytokines or immune molecules, scFv antibodies may be used to treat autoimmune diseases.

Alpha Lifetech provides scFv Antibody Production services, covering the entire process from gene sequence design to antibody purification, to ensure excellent products for our customers. We have extensive experience in the field of antibody engineering and can support diverse projects ranging from small-scale research level production to large-scale industrial applications. Alpha Lifetech also provides personalized customization services to optimize antibody properties such as stability and efficiency based on specific customer needs.